前立腺肥大症の世界市場成長(現状と展望)2024-2030年Global Benign Prostatic Hyperplasia Market Growth (Status and Outlook) 2024-2030 前立腺肥大症(BPH)は前立腺肥大症とも呼ばれ、前立腺細胞の異常な増殖が特徴で、尿閉や尿路感染症などの難病を引き起こす。前立腺肥大症は高齢化した男性に最も多く見られ、主にこの市場を牽引している。地域別... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー前立腺肥大症(BPH)は前立腺肥大症とも呼ばれ、前立腺細胞の異常な増殖が特徴で、尿閉や尿路感染症などの難病を引き起こす。前立腺肥大症は高齢化した男性に最も多く見られ、主にこの市場を牽引している。地域別分析では、医療インフラの充実、泌尿器科疾患に対する医療費の高騰、社会的認知度の向上による外来患者数や病院受診数の増加などから、北米地域が同市場における優位性を維持すると予想される。世界の前立腺肥大症の市場規模は、2023年の1億米ドルから2030年には1億4,050万米ドルに成長すると予測されており、2024年から2030年までの年平均成長率は5.0%で推移すると予測されています。 LPI(エルピーアイ情報)の最新調査レポート「前立腺肥大症産業予測」は、過去の売上高を調べ、2023年の世界の前立腺肥大症売上高合計をレビューし、2024年から2030年までの前立腺肥大症売上高予測について地域別・市場分野別に包括的な分析を提供しています。前立腺肥大症の売上高を地域別、市場分野別、サブセクター別に分類し、世界の前立腺肥大症産業の詳細な分析を百万米ドル単位で提供します。 本インサイトレポートは、世界の前立腺肥大症の状況を包括的に分析し、製品セグメンテーション、企業形成、収益、市場シェア、最新開発、M&A活動に関する主要動向を明らかにします。また、本レポートでは、前立腺肥大症のポートフォリオと能力、市場参入戦略、市場での地位、地理的な足跡に焦点を当てて、世界の主要企業の戦略を分析し、加速する世界の前立腺肥大症市場におけるこれらの企業の独自の地位をより深く理解します。 この調査レポートは、前立腺肥大症の世界的な見通しを形成する主要な市場動向、促進要因、影響要因を評価し、タイプ別、用途別、地域別、市場規模別に予測を細分化して、新たな機会のポケットを浮き彫りにします。何百ものボトムアップの定性的・定量的市場インプットに基づいた透明性の高い手法により、この調査予測は世界の前立腺肥大症の現状と将来の軌道について非常にニュアンスのある見解を提供します。 米国の前立腺肥大症市場は、2023年の100万米ドルから2030年には100万米ドルに増加し、2024年から2030年までの年平均成長率は%と推定される。 前立腺肥大症の中国市場は、2023年の100万米ドルから2030年には100万米ドルに、2024年から2030年までの年平均成長率は%と推定される。 欧州の前立腺肥大症市場は、2023年の100万米ドルから2030年には100万米ドルに増加し、2024年から2030年までの年平均成長率は%と推定される。 世界の主要な前立腺肥大症のプレーヤーは、アボット、アラガン、アステラス製薬、ベーリンガーインゲルハイム製薬、イーライリリー・アンド・カンパニーなどをカバーしている。売上高では、世界の大手2社が2023年にほぼ%のシェアを占めています。 当レポートでは、前立腺肥大症市場の包括的な概要、市場シェア、成長機会を、製品タイプ別、用途別、主要企業別、主要地域別および国別に紹介しています。 タイプ別セグメンテーション 薬物療法 透析療法 その他 用途別セグメンテーション 病院 診療所 本レポートは地域別にも市場を分割しています: 南北アメリカ アメリカ カナダ メキシコ ブラジル APAC 中国 日本 韓国 東南アジア インド オーストラリア ヨーロッパ ドイツ フランス 英国 イタリア ロシア 中東・アフリカ エジプト 南アフリカ イスラエル トルコ GCC諸国 以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。 アボット アラガン アステラス製薬 ベーリンガーインゲルハイム製薬 イーライリリー・アンド・カンパニー グラクソ・スミスクライン メルク ファイザー サノフィ 目次1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Benign Prostatic Hyperplasia Market Size 2019-2030 2.1.2 Benign Prostatic Hyperplasia Market Size CAGR by Region 2019 VS 2023 VS 2030 2.2 Benign Prostatic Hyperplasia Segment by Type 2.2.1 Drug Therapy 2.2.2 Dialysis 2.2.3 Others 2.3 Benign Prostatic Hyperplasia Market Size by Type 2.3.1 Benign Prostatic Hyperplasia Market Size CAGR by Type (2019 VS 2023 VS 2030) 2.3.2 Global Benign Prostatic Hyperplasia Market Size Market Share by Type (2019-2024) 2.4 Benign Prostatic Hyperplasia Segment by Application 2.4.1 Hospitals 2.4.2 Clinics 2.5 Benign Prostatic Hyperplasia Market Size by Application 2.5.1 Benign Prostatic Hyperplasia Market Size CAGR by Application (2019 VS 2023 VS 2030) 2.5.2 Global Benign Prostatic Hyperplasia Market Size Market Share by Application (2019-2024) 3 Benign Prostatic Hyperplasia Market Size by Player 3.1 Benign Prostatic Hyperplasia Market Size Market Share by Players 3.1.1 Global Benign Prostatic Hyperplasia Revenue by Players (2019-2024) 3.1.2 Global Benign Prostatic Hyperplasia Revenue Market Share by Players (2019-2024) 3.2 Global Benign Prostatic Hyperplasia Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion 4 Benign Prostatic Hyperplasia by Regions 4.1 Benign Prostatic Hyperplasia Market Size by Regions (2019-2024) 4.2 Americas Benign Prostatic Hyperplasia Market Size Growth (2019-2024) 4.3 APAC Benign Prostatic Hyperplasia Market Size Growth (2019-2024) 4.4 Europe Benign Prostatic Hyperplasia Market Size Growth (2019-2024) 4.5 Middle East & Africa Benign Prostatic Hyperplasia Market Size Growth (2019-2024) 5 Americas 5.1 Americas Benign Prostatic Hyperplasia Market Size by Country (2019-2024) 5.2 Americas Benign Prostatic Hyperplasia Market Size by Type (2019-2024) 5.3 Americas Benign Prostatic Hyperplasia Market Size by Application (2019-2024) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Benign Prostatic Hyperplasia Market Size by Region (2019-2024) 6.2 APAC Benign Prostatic Hyperplasia Market Size by Type (2019-2024) 6.3 APAC Benign Prostatic Hyperplasia Market Size by Application (2019-2024) 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe Benign Prostatic Hyperplasia by Country (2019-2024) 7.2 Europe Benign Prostatic Hyperplasia Market Size by Type (2019-2024) 7.3 Europe Benign Prostatic Hyperplasia Market Size by Application (2019-2024) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Benign Prostatic Hyperplasia by Region (2019-2024) 8.2 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Type (2019-2024) 8.3 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Application (2019-2024) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Global Benign Prostatic Hyperplasia Market Forecast 10.1 Global Benign Prostatic Hyperplasia Forecast by Regions (2025-2030) 10.1.1 Global Benign Prostatic Hyperplasia Forecast by Regions (2025-2030) 10.1.2 Americas Benign Prostatic Hyperplasia Forecast 10.1.3 APAC Benign Prostatic Hyperplasia Forecast 10.1.4 Europe Benign Prostatic Hyperplasia Forecast 10.1.5 Middle East & Africa Benign Prostatic Hyperplasia Forecast 10.2 Americas Benign Prostatic Hyperplasia Forecast by Country (2025-2030) 10.2.1 United States Benign Prostatic Hyperplasia Market Forecast 10.2.2 Canada Benign Prostatic Hyperplasia Market Forecast 10.2.3 Mexico Benign Prostatic Hyperplasia Market Forecast 10.2.4 Brazil Benign Prostatic Hyperplasia Market Forecast 10.3 APAC Benign Prostatic Hyperplasia Forecast by Region (2025-2030) 10.3.1 China Benign Prostatic Hyperplasia Market Forecast 10.3.2 Japan Benign Prostatic Hyperplasia Market Forecast 10.3.3 Korea Benign Prostatic Hyperplasia Market Forecast 10.3.4 Southeast Asia Benign Prostatic Hyperplasia Market Forecast 10.3.5 India Benign Prostatic Hyperplasia Market Forecast 10.3.6 Australia Benign Prostatic Hyperplasia Market Forecast 10.4 Europe Benign Prostatic Hyperplasia Forecast by Country (2025-2030) 10.4.1 Germany Benign Prostatic Hyperplasia Market Forecast 10.4.2 France Benign Prostatic Hyperplasia Market Forecast 10.4.3 UK Benign Prostatic Hyperplasia Market Forecast 10.4.4 Italy Benign Prostatic Hyperplasia Market Forecast 10.4.5 Russia Benign Prostatic Hyperplasia Market Forecast 10.5 Middle East & Africa Benign Prostatic Hyperplasia Forecast by Region (2025-2030) 10.5.1 Egypt Benign Prostatic Hyperplasia Market Forecast 10.5.2 South Africa Benign Prostatic Hyperplasia Market Forecast 10.5.3 Israel Benign Prostatic Hyperplasia Market Forecast 10.5.4 Turkey Benign Prostatic Hyperplasia Market Forecast 10.5.5 GCC Countries Benign Prostatic Hyperplasia Market Forecast 10.6 Global Benign Prostatic Hyperplasia Forecast by Type (2025-2030) 10.7 Global Benign Prostatic Hyperplasia Forecast by Application (2025-2030) 11 Key Players Analysis 11.1 Abbott 11.1.1 Abbott Company Information 11.1.2 Abbott Benign Prostatic Hyperplasia Product Offered 11.1.3 Abbott Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.1.4 Abbott Main Business Overview 11.1.5 Abbott Latest Developments 11.2 Allergan 11.2.1 Allergan Company Information 11.2.2 Allergan Benign Prostatic Hyperplasia Product Offered 11.2.3 Allergan Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.2.4 Allergan Main Business Overview 11.2.5 Allergan Latest Developments 11.3 Astellas Pharma 11.3.1 Astellas Pharma Company Information 11.3.2 Astellas Pharma Benign Prostatic Hyperplasia Product Offered 11.3.3 Astellas Pharma Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.3.4 Astellas Pharma Main Business Overview 11.3.5 Astellas Pharma Latest Developments 11.4 Boehringer Ingelheim Pharma 11.4.1 Boehringer Ingelheim Pharma Company Information 11.4.2 Boehringer Ingelheim Pharma Benign Prostatic Hyperplasia Product Offered 11.4.3 Boehringer Ingelheim Pharma Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.4.4 Boehringer Ingelheim Pharma Main Business Overview 11.4.5 Boehringer Ingelheim Pharma Latest Developments 11.5 Eli Lilly and Company 11.5.1 Eli Lilly and Company Company Information 11.5.2 Eli Lilly and Company Benign Prostatic Hyperplasia Product Offered 11.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.5.4 Eli Lilly and Company Main Business Overview 11.5.5 Eli Lilly and Company Latest Developments 11.6 GlaxoSmithKline 11.6.1 GlaxoSmithKline Company Information 11.6.2 GlaxoSmithKline Benign Prostatic Hyperplasia Product Offered 11.6.3 GlaxoSmithKline Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.6.4 GlaxoSmithKline Main Business Overview 11.6.5 GlaxoSmithKline Latest Developments 11.7 Merck 11.7.1 Merck Company Information 11.7.2 Merck Benign Prostatic Hyperplasia Product Offered 11.7.3 Merck Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.7.4 Merck Main Business Overview 11.7.5 Merck Latest Developments 11.8 Pfizer 11.8.1 Pfizer Company Information 11.8.2 Pfizer Benign Prostatic Hyperplasia Product Offered 11.8.3 Pfizer Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.8.4 Pfizer Main Business Overview 11.8.5 Pfizer Latest Developments 11.9 Sanofi 11.9.1 Sanofi Company Information 11.9.2 Sanofi Benign Prostatic Hyperplasia Product Offered 11.9.3 Sanofi Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.9.4 Sanofi Main Business Overview 11.9.5 Sanofi Latest Developments 12 Research Findings and Conclusion
SummaryBenign prostatic hyperplasia (BPH) also known as benign prostatic hypertrophy is characterized by the unusual propagation of the prostatic cells, which causes difficulties like urinary retention and infections of the urinary tract. It is most common among the aging men population, primarily driving this market. On the basis of geographical analysis, the North American region is expected to retain its dominance in this market owing to better healthcare infrastructure, high healthcare expenditure on urological disorders, increased awareness in the society increasing the outpatients center and hospitals visits. Table of Contents1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Benign Prostatic Hyperplasia Market Size 2019-2030 2.1.2 Benign Prostatic Hyperplasia Market Size CAGR by Region 2019 VS 2023 VS 2030 2.2 Benign Prostatic Hyperplasia Segment by Type 2.2.1 Drug Therapy 2.2.2 Dialysis 2.2.3 Others 2.3 Benign Prostatic Hyperplasia Market Size by Type 2.3.1 Benign Prostatic Hyperplasia Market Size CAGR by Type (2019 VS 2023 VS 2030) 2.3.2 Global Benign Prostatic Hyperplasia Market Size Market Share by Type (2019-2024) 2.4 Benign Prostatic Hyperplasia Segment by Application 2.4.1 Hospitals 2.4.2 Clinics 2.5 Benign Prostatic Hyperplasia Market Size by Application 2.5.1 Benign Prostatic Hyperplasia Market Size CAGR by Application (2019 VS 2023 VS 2030) 2.5.2 Global Benign Prostatic Hyperplasia Market Size Market Share by Application (2019-2024) 3 Benign Prostatic Hyperplasia Market Size by Player 3.1 Benign Prostatic Hyperplasia Market Size Market Share by Players 3.1.1 Global Benign Prostatic Hyperplasia Revenue by Players (2019-2024) 3.1.2 Global Benign Prostatic Hyperplasia Revenue Market Share by Players (2019-2024) 3.2 Global Benign Prostatic Hyperplasia Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion 4 Benign Prostatic Hyperplasia by Regions 4.1 Benign Prostatic Hyperplasia Market Size by Regions (2019-2024) 4.2 Americas Benign Prostatic Hyperplasia Market Size Growth (2019-2024) 4.3 APAC Benign Prostatic Hyperplasia Market Size Growth (2019-2024) 4.4 Europe Benign Prostatic Hyperplasia Market Size Growth (2019-2024) 4.5 Middle East & Africa Benign Prostatic Hyperplasia Market Size Growth (2019-2024) 5 Americas 5.1 Americas Benign Prostatic Hyperplasia Market Size by Country (2019-2024) 5.2 Americas Benign Prostatic Hyperplasia Market Size by Type (2019-2024) 5.3 Americas Benign Prostatic Hyperplasia Market Size by Application (2019-2024) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Benign Prostatic Hyperplasia Market Size by Region (2019-2024) 6.2 APAC Benign Prostatic Hyperplasia Market Size by Type (2019-2024) 6.3 APAC Benign Prostatic Hyperplasia Market Size by Application (2019-2024) 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe Benign Prostatic Hyperplasia by Country (2019-2024) 7.2 Europe Benign Prostatic Hyperplasia Market Size by Type (2019-2024) 7.3 Europe Benign Prostatic Hyperplasia Market Size by Application (2019-2024) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Benign Prostatic Hyperplasia by Region (2019-2024) 8.2 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Type (2019-2024) 8.3 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Application (2019-2024) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Global Benign Prostatic Hyperplasia Market Forecast 10.1 Global Benign Prostatic Hyperplasia Forecast by Regions (2025-2030) 10.1.1 Global Benign Prostatic Hyperplasia Forecast by Regions (2025-2030) 10.1.2 Americas Benign Prostatic Hyperplasia Forecast 10.1.3 APAC Benign Prostatic Hyperplasia Forecast 10.1.4 Europe Benign Prostatic Hyperplasia Forecast 10.1.5 Middle East & Africa Benign Prostatic Hyperplasia Forecast 10.2 Americas Benign Prostatic Hyperplasia Forecast by Country (2025-2030) 10.2.1 United States Benign Prostatic Hyperplasia Market Forecast 10.2.2 Canada Benign Prostatic Hyperplasia Market Forecast 10.2.3 Mexico Benign Prostatic Hyperplasia Market Forecast 10.2.4 Brazil Benign Prostatic Hyperplasia Market Forecast 10.3 APAC Benign Prostatic Hyperplasia Forecast by Region (2025-2030) 10.3.1 China Benign Prostatic Hyperplasia Market Forecast 10.3.2 Japan Benign Prostatic Hyperplasia Market Forecast 10.3.3 Korea Benign Prostatic Hyperplasia Market Forecast 10.3.4 Southeast Asia Benign Prostatic Hyperplasia Market Forecast 10.3.5 India Benign Prostatic Hyperplasia Market Forecast 10.3.6 Australia Benign Prostatic Hyperplasia Market Forecast 10.4 Europe Benign Prostatic Hyperplasia Forecast by Country (2025-2030) 10.4.1 Germany Benign Prostatic Hyperplasia Market Forecast 10.4.2 France Benign Prostatic Hyperplasia Market Forecast 10.4.3 UK Benign Prostatic Hyperplasia Market Forecast 10.4.4 Italy Benign Prostatic Hyperplasia Market Forecast 10.4.5 Russia Benign Prostatic Hyperplasia Market Forecast 10.5 Middle East & Africa Benign Prostatic Hyperplasia Forecast by Region (2025-2030) 10.5.1 Egypt Benign Prostatic Hyperplasia Market Forecast 10.5.2 South Africa Benign Prostatic Hyperplasia Market Forecast 10.5.3 Israel Benign Prostatic Hyperplasia Market Forecast 10.5.4 Turkey Benign Prostatic Hyperplasia Market Forecast 10.5.5 GCC Countries Benign Prostatic Hyperplasia Market Forecast 10.6 Global Benign Prostatic Hyperplasia Forecast by Type (2025-2030) 10.7 Global Benign Prostatic Hyperplasia Forecast by Application (2025-2030) 11 Key Players Analysis 11.1 Abbott 11.1.1 Abbott Company Information 11.1.2 Abbott Benign Prostatic Hyperplasia Product Offered 11.1.3 Abbott Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.1.4 Abbott Main Business Overview 11.1.5 Abbott Latest Developments 11.2 Allergan 11.2.1 Allergan Company Information 11.2.2 Allergan Benign Prostatic Hyperplasia Product Offered 11.2.3 Allergan Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.2.4 Allergan Main Business Overview 11.2.5 Allergan Latest Developments 11.3 Astellas Pharma 11.3.1 Astellas Pharma Company Information 11.3.2 Astellas Pharma Benign Prostatic Hyperplasia Product Offered 11.3.3 Astellas Pharma Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.3.4 Astellas Pharma Main Business Overview 11.3.5 Astellas Pharma Latest Developments 11.4 Boehringer Ingelheim Pharma 11.4.1 Boehringer Ingelheim Pharma Company Information 11.4.2 Boehringer Ingelheim Pharma Benign Prostatic Hyperplasia Product Offered 11.4.3 Boehringer Ingelheim Pharma Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.4.4 Boehringer Ingelheim Pharma Main Business Overview 11.4.5 Boehringer Ingelheim Pharma Latest Developments 11.5 Eli Lilly and Company 11.5.1 Eli Lilly and Company Company Information 11.5.2 Eli Lilly and Company Benign Prostatic Hyperplasia Product Offered 11.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.5.4 Eli Lilly and Company Main Business Overview 11.5.5 Eli Lilly and Company Latest Developments 11.6 GlaxoSmithKline 11.6.1 GlaxoSmithKline Company Information 11.6.2 GlaxoSmithKline Benign Prostatic Hyperplasia Product Offered 11.6.3 GlaxoSmithKline Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.6.4 GlaxoSmithKline Main Business Overview 11.6.5 GlaxoSmithKline Latest Developments 11.7 Merck 11.7.1 Merck Company Information 11.7.2 Merck Benign Prostatic Hyperplasia Product Offered 11.7.3 Merck Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.7.4 Merck Main Business Overview 11.7.5 Merck Latest Developments 11.8 Pfizer 11.8.1 Pfizer Company Information 11.8.2 Pfizer Benign Prostatic Hyperplasia Product Offered 11.8.3 Pfizer Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.8.4 Pfizer Main Business Overview 11.8.5 Pfizer Latest Developments 11.9 Sanofi 11.9.1 Sanofi Company Information 11.9.2 Sanofi Benign Prostatic Hyperplasia Product Offered 11.9.3 Sanofi Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024) 11.9.4 Sanofi Main Business Overview 11.9.5 Sanofi Latest Developments 12 Research Findings and Conclusion
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
LP Information社の医療分野での最新刊レポート
本レポートと同じKEY WORD()の最新刊レポート
よくあるご質問LP Information社はどのような調査会社ですか?LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|